Literature DB >> 4064451

Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

R Riva, M Contin, F Albani, E Perucca, G Procaccianti, A Baruzzi.   

Abstract

Total and free plasma concentrations of carbamazepine (CBZ) and carbamazepine-10,11-epoxide (CBZ-E) were determined in 39 children (aged 3 to 10 years) and 79 adults (aged 15 to 65 years) receiving long term treatment with CBZ alone or in combination with phenobarbitone (PB). Compared with the corresponding age groups treated with CBZ alone, adults and children receiving PB co-medication showed lower total and free CBZ concentrations, similar CBZ-E concentrations and higher CBZ-E/CBZ ratios. Among patients on CBZ alone, children had at any given dose lower total and free CBZ and CBZ-E concentrations than adults. Lower CBZ levels in children than in adults were also found among patients receiving phenobarbitone in combination. CBZ-E/CBZ ratios did not differ significantly between children and adults. These data provide evidence that children show an elevated free CBZ clearance with a metabolic pattern different from that observed during phenobarbitone induction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064451     DOI: 10.2165/00003088-198510060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  26 in total

1.  Possible hazard of valpromide-carbamazepine combination therapy in epilepsy.

Authors:  J W Meijer; C D Binnie; R M Debets; J A van Parys; N K de Beer-Pawlikowski
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

2.  Protein binding of carbamazepine in epileptic patients.

Authors:  L M Lawless; H J DeMonaco; L R Muido
Journal:  Neurology       Date:  1982-04       Impact factor: 9.910

3.  Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

Authors:  R Riva; F Albani; G Ambrosetto; M Contin; P Cortelli; E Perucca; A Baruzzi
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

4.  Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy.

Authors:  D Battino; L Bossi; D Croci; S Franceschetti; C Gomeni; A Moise; A Vitali
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

5.  Effect of dose increments on serum carbamazepine concentration in epileptic patients.

Authors:  E Perucca; P Bittencourt; A Richens
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

6.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

7.  Filtration for free drug level monitoring: carbamazepine and valproic acid.

Authors:  R H Levy; P N Friel; I Johno; L M Linthicum; L Colin; K Koch; V A Raisys; A J Wilensky; N R Temkin
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

8.  Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects.

Authors:  T Tomson
Journal:  Arch Neurol       Date:  1984-08

9.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

10.  Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey.

Authors:  P J Wedlund; I H Patel; R H Levy
Journal:  J Pharmacokinet Biopharm       Date:  1982-08
View more
  7 in total

1.  What is the right dose for children?

Authors:  Massimo Cella; Catherijne Knibbe; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 2.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

3.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

4.  Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.

Authors:  B Summers; R S Summers
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

Review 6.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

7.  Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy.

Authors:  J Ben Renfroe; Mark Mintz; Ronald Davis; Jose Ferreira; Sharon Dispoto; Jim Ferry; Yuko Umetsu; Bhaskar Rege; Oneeb Majid; Ziad Hussein; Antonio Laurenza
Journal:  J Child Neurol       Date:  2019-02-10       Impact factor: 1.987

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.